AI 'Super-Vision' for Surgeons Secures £17M in Major HealthTech Deal

ROME, ITALY – April 29, 2026 – A future where surgeons possess a form of 'super-vision'—seeing critical tissue information invisible to the naked eye—has moved a significant step closer to reality. Hypervision Surgical, a UK-based pioneer in advanced surgical imaging, has closed an oversubscribed £17 million Series A funding round, with notable participation from Angelini Ventures, the corporate venture arm of Angelini Industries.

The investment is a major vote of confidence in Hypervision Surgical's mission to revolutionize surgery by integrating artificial intelligence with hyperspectral imaging. The funds are earmarked to accelerate the commercial rollout and clinical adoption of its groundbreaking Hyperspectral Intelligence® platform, potentially setting a new, data-driven standard of care in operating rooms worldwide.

A New Layer of Surgical Intelligence

At the core of this innovation is a technology that fundamentally enhances what a surgeon sees. While conventional surgical cameras provide a high-definition view, they are still limited to the visible light spectrum. Hypervision Surgical's platform captures and analyzes information across a much broader range of light, revealing physiological details of tissue in real-time.

By combining on-chip spectral sensing with patented AI analytics, the Hyperspectral Intelligence® platform generates live, quantitative maps of tissue properties like oxygenation, without the need for injectable dyes. This provides surgeons with objective, data-driven insights that were previously impossible to access during a procedure. The company's goal is to integrate this technology into the laparoscopic, robotic, microscopic, and endoscopic systems used in hundreds of millions of surgeries each year.

“This Series A marks a major milestone in our mission to power surgical intelligence through hyperspectral vision,” said Michael Ebner, CEO and Co-Founder of Hypervision Surgical. “By combining advanced spectral sensing with cloud-enabled AI analytics, we are building a new intelligence layer in surgery – giving surgeons real-time insights into tissue that were previously impossible to access.”

The company’s commercial system, HYPERSNAP®, leverages the advanced edge computing power of the NVIDIA IGX architecture to perform this complex AI inference in the demanding, real-time environment of the operating room.

Smart Capital Bets on a Sharper Scalpel

The oversubscribed funding round, led by European HealthTech fund Heal Capital, signals strong investor belief in both the technology's potential and the market's readiness. The participation of Angelini Ventures, a firm with a €300 million capital commitment to disruptive BioTech and HealthTech, underscores the strategic importance of Hypervision's approach.

As part of the deal, Angelini Ventures Managing Partner Tanja Dowe will join Hypervision Surgical’s Board of Directors. Dowe brings over two decades of experience in the life sciences sector, having previously built a significant portfolio of digital health companies.

“We believe Hypervision Surgical is redefining what is possible in surgical visualization," said Tanja Dowe. "Hypervision’s technology has the potential to significantly improve surgical outcomes and patient safety. We are excited to support the team as they scale this breakthrough platform and bring it into clinical practice.”

The investor syndicate is notable not just for its financial power but also for its strategic depth. It includes existing investors like IP Group, HERAN Partners, and ZEISS Ventures, alongside new strategic investments from the SINC Fund, managed by the innovation arm of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), and Macmillan Cancer Support, the UK's leading cancer charity. This broad coalition provides validation from the clinical, patient, and venture capital communities alike.

From Lab to Operating Room: The Path to Safer Surgery

Born from research at King’s College London, Hypervision Surgical has navigated the complex path from academic concept to a clinically-ready and regulator-approved medical device. The HYPERSNAP® system has already achieved significant milestones, including UKCA marking in the United Kingdom and, crucially, 510(k) clearance from the U.S. Food and Drug Administration (FDA).

The FDA clearance is particularly noteworthy, as the agency created a new product code specifically for AI-based real-time video augmentation in surgery to accommodate Hypervision's novel technology. Furthermore, the system was selected for the FDA's Safer Technologies Program (STeP), a program that fast-tracks devices recognized for their potential to significantly improve the safety of existing medical procedures.

The clinical applications are profound. One of the primary initial targets is colorectal surgery, where the technology aims to help surgeons better assess tissue viability when joining sections of the bowel. This could significantly reduce the rate of anastomotic leakage, a severe and life-threatening complication. Early clinical evaluations are already underway in UK hospitals, with initial findings set to be presented at major surgical conferences. The involvement of Macmillan Cancer Support highlights the immense potential for improving outcomes in cancer surgery, where distinguishing between healthy and cancerous tissue is paramount.

The AI-Augmented Surgeon: Promise and Prudence

The rise of technologies like Hyperspectral Intelligence® fuels a broader conversation about the future of the operating room. The global market for AI in medical imaging is projected to grow exponentially, with some estimates suggesting a compound annual growth rate of over 34% to reach nearly $20 billion by 2033. This growth is driven by the promise of enhanced precision, improved diagnostics, and more efficient healthcare delivery.

Experts largely agree that AI will not replace surgeons but will instead augment their skills, creating a new paradigm of "the AI-assisted surgeon." By processing vast datasets and revealing hidden patterns, AI can act as a powerful co-pilot, helping to standardize high-quality outcomes and reduce human error. This could also revolutionize surgical training, providing trainees with advanced simulations and objective feedback.

However, the rapid integration of AI into such a critical field is not without challenges. Important questions surrounding accountability for errors, the potential for algorithmic bias, data privacy, and the risk of surgeon skill atrophy due to over-reliance on technology are at the forefront of ethical discussions. Ensuring equitable access to these expensive technologies is another critical concern, to avoid widening the gap in healthcare quality between different regions and socioeconomic groups.

Hypervision Surgical's strategy to integrate its software-centric platform across a wide range of existing surgical hardware—from open surgery to robotics—may offer a path to broader accessibility. By transforming traditional surgical cameras into data-rich diagnostic tools, the technology promises a future where enhanced surgical vision is not a luxury, but a fundamental component of safe and effective patient care.